Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 445 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Healthy
Interventions: Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen; Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: South Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Concord, California + 43 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Liraglutide, Metformin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Montclair, California • Daytona Beach, Florida + 6 more

Conditions: Weight Maintenance
Interventions: Digital Behavioral Application; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions: Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 887,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autosomal Dominant Polycystic Kidney, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
Interventions: Tirzepatide; Drug
Lead sponsor: Grace Kim; Other
Eligibility: 18 Years to 26 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Nashville, Tennessee • Seattle, Washington

Conditions: Congenital Hyperinsulinism
Interventions: Exendin-(9-39), Vehicle; Drug · Other
Lead sponsor: Diva De Leon; Other
Eligibility: 7 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Liraglutide 1.8mg, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 2 Diabetes (Adult Onset)
Interventions: Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Maturity Onset Diabetes of the Young
Interventions: Liraglutide; Drug
Lead sponsor: Mansa; Other
Eligibility: 10 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Post Bariatricsurgery, Hypoglycemia
Interventions: Exendin-(9-39), Atropine, GLP-1 and GIP; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Obesity/Therapy
Interventions: Semaglutide 1.7mg subcutaneous, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions: Dulaglutide 0.75Mg/0.5Ml Inj Pen; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Saline Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions: Tirzepatide, Semaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-Diabetes
Interventions: Liraglutide, Weight loss; Drug · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Torrance, California • Houston, Texas

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Methamphetamine Use Disorder
Interventions: Tirzepatide, Placebo (saline); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Hyperglycemia, Hypoglycemia
Interventions: GLP 1, normal saline solution placebo; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight and Obesity
Interventions: 24-hour ambulatory blood pressure, Liberal salt diet; Diagnostic Test · Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Menopause Hot Flashes
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 46 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Tirzepatide in PWS, HO and GNSO

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Liraglutide in Type 1 Diabetes

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Study of Tirzepatide for Recovery and Alcohol Use Management

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Improving Beta Cell Function in Mexican American Women With Prediabetes

Anti-obesity Pharmacotherapy and Inflammation

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

GLP 1 for Intraoperative Glycemic Control

Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity